Marcin Cieslik
Differentiating indolent from aggressive prostate tumors is critical for early detection of aggressive tumors and prevention of overtreatment. Pseudogenes are dysfunctional relatives of genes that have lost their ability to...Read More
Theodoros Karantanos
Certain oncogenic molecules in prostate cancer cells regulate cellular metabolism in the tumor microenvironment, allowing tumor cells to proliferate under harsh conditions. Dr. Karantanos believes that a program of oncogenic...Read More
W. Nathaniel Brennen
T cells are a type of immune cell with significant tumor cell seeking and killing capabilities, but tumor survival mechanisms cause T cell inactivation. Methods for re-arming these specialized killing...Read More
Andrew Armstrong
Dr. Armstrong earned a BS in Biomedical Engineering from Duke University, an MD degree from the University of Virginia and an MS in Clinical Investigation from Johns Hopkins University. He...Read More
Vivek Arora
Preclinical assessment of mechanisms of resistance to hormone therapy in prostate cancer has led to the discovery and development of a new medicine, named ARN-509. Dr. Arora has shown that...Read More
Jennifer Bishop
Approximately 25% of patients who fail Xtandi and Zytiga present with a lethal form of prostate cancer named neuroendocrine prostate cancer (NEPC). Features of NEPC include changes in hormonal sensitivity,...Read More
Irfan Asangani
The organization of DNA into super-structures is an ordered and normal process of cell growth that is dysregulated in cancer. Chemical modifications of DNA have been identified by Dr. Irfan...Read More
Charles Chan
Engraftment of prostate cancer in bone heralds a lethal form of the disease. New targets are needed for the treatment of prostate cancer in bone and to prevent bone localization...Read More